1. Home
  2. ZLAB vs NVAX Comparison

ZLAB vs NVAX Comparison

Compare ZLAB & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zai Lab Limited

ZLAB

Zai Lab Limited

HOLD

Current Price

$25.63

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$9.96

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZLAB
NVAX
Founded
2013
1987
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
1.3B
IPO Year
2017
1996

Fundamental Metrics

Financial Performance
Metric
ZLAB
NVAX
Price
$25.63
$9.96
Analyst Decision
Strong Buy
Hold
Analyst Count
5
9
Target Price
$49.60
$11.33
AVG Volume (30 Days)
818.3K
5.3M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
38.46
309.76
EPS
N/A
N/A
Revenue
$460,156,000.00
$1,123,479,000.00
Revenue This Year
$9.75
N/A
Revenue Next Year
$26.03
N/A
P/E Ratio
N/A
N/A
Revenue Growth
15.33
64.69
52 Week Low
$15.96
$6.20
52 Week High
$34.72
$11.85

Technical Indicators

Market Signals
Indicator
ZLAB
NVAX
Relative Strength Index (RSI) 56.31 60.72
Support Level $24.81 $9.12
Resistance Level $27.22 $10.36
Average True Range (ATR) 0.90 0.62
MACD -0.23 -0.03
Stochastic Oscillator 51.30 54.53

Price Performance

Historical Comparison
ZLAB
NVAX

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Share on Social Networks: